万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址：
https://www.sciencedirect.com/journal/pharmacological-research-modern-chinese-medicine
4、投稿网址：
https://www.editorialmanager.com/prmcm/default.aspx
5、主办单位官网：
http://www.cnphars.org.cn/view.asp?ar_id=1935&anclassid=6&nclassid=
（中国药理学会）
6、期刊刊期：季刊，逢季末月出版。
7、在2023年前投稿免收稿件处理费。
（主办单位官网信息）
2023年12月31日前投稿的文章，作者无须支付文章出版费（APC）。
（微信公众号“爱思唯尔Elsevier”信息）
2021年9月8日星期三
《药理研究：现代中医（英文）》创刊
（Pharmacological Reseach-Modern Chinese Medicine）
【主办单位官网信息】
2019年初，在IUPHAR前主席S J Enna教授的积极推荐下，国际知名科技出版集团Elsevier（爱思唯尔）药学出版人Anne Marie Pordon女士开始与我会沟通，计划创办一份以中药药理学为主要内容的新期刊。与本领域已有期刊相比，本刊最大的特点是可以接受中药复方药理学研究的文章，而不局限于分离纯化获得的活性成分/单体的药理学研究。
学会领导对此计划表示大力支持，认为这是加强中药药理学国际学术交流、向世界介绍中医药的科研成果、促进中医药国际发展的一条重要途径，并着手与Elsevier进行讨论协商。2019年，学会领导先后在第三届中美双边药理学术会议和中国药理学会第十五次全国学术大会期间，与Enna教授和Pordon女士会面，商讨办刊事宜。2020年尽管面临全球疫情的不利影响，双方也利用邮件、视频会议等方式保持密切沟通，于2020年底就办刊计划基本达成一致，开始研究合作协议。
2021年5月，经双方协商一致，中国药理学会与Elsevier达成一致，正式签署合作办刊协议。期刊正式名称为Pharmacological Research: Modern Chinese Medicine，采取双主编负责制，由我会和Elsevier各推荐一位，经推荐和协商，我会党委书记杜冠华教授和意大利米兰大学Emilio Clementi教授担任共同主编，我会段大跃教授、高秀梅教授、周文霞教授担任副主编，另有62名专家担任编委。本刊为开放获取期刊（Open Access, OA），在2023年前投稿免收稿件处理费。6月17日，Elsevier正式通过官网发布消息，期刊自即日起接受投稿。本刊主要刊登实验药理学相关的机制研究、安全性研究，药理学活性物质及中药复方的临床疗效研究、安全性研究等相关领域文章，鼓励将现代科学方法应用于中药复方的研究中。同时欢迎活性物质作用机制研究等相关领域文章投稿。
中药复方是在中医理论指导下、由两味及以上中药配伍组成，是中医防治疾病的主要形式，具有数千年的历史，是经验和智慧的结晶，蕴含了深刻的科学内涵。其有效性和临床价值在长期临床实践中得到了充分证明，为中华民族健康繁衍生息做出了重要贡献，在世界天然药物和传统药物发展史上占有重要地位，正在得到世界范围内越来越多的了解和认可。我会与国际顶级出版集团合作创办中医药领域新刊，对于进一步发扬中医药的传统优势、加强中药现代研究、促进中医药国际学术交流与合作、让中医药惠及世界等，均具有重要意义。
《药理研究：现代中医（英文）》期刊信息
（Pharmacological Reseach-Modern Chinese Medicine）
【微信公众号“爱思唯尔Elsevier”信息】
爱思唯尔Elsevier 2021-06-17
爱思唯尔和中国药理学会合作创办的开放获取期刊Pharmacological Research - Modern Chinese Medicine正式发布，现已接收作者投稿！
Pharmacological Research - Modern Chinese Medicine期刊主要刊登实验药理学相关的机制研究、安全性研究，药理学活性物质及中药复方的临床疗效研究、安全性研究等相关领域文章，鼓励将现代科学方法应用于中药复方的研究之中。同时欢迎活性物质作用机制研究等相关领域文章投稿。
限免政策：2023年12月31日前投稿的文章，作者无须支付文章出版费（APC）！
主编简介
Emilio Clementi博士自2005年起任意大利米兰大学药理学教授兼国家卫生系统临床药理学组主任，1988年在米兰大学(University of Milano)获得医学博士学位，并于1994年在布雷西亚大学(University of Brescia)获得了实验药物治疗博士学位。目前是欧洲临床药理学和治疗学协会（EACPT）执行委员会成员，他还是国际基础和临床药理学联盟（IUPHAR）执行委员会成员。重点研究一氧化氮的病理生理学及其在治疗方面的相关性，并且研究了其在杜兴氏肌肉营养不良症临床研究中的作用。除本刊外，Emilio Clementi还担任爱思唯尔期刊Pharmacological Research主编，发表论文400余篇（H指数53）。
杜冠华，药理学教授，国际欧亚科学院院士，中国药理学会原理事长。兼任国际基础与临床药理学联合会（IUPHAR）执行委员会委员；亚太药理学家联盟（APFP）执行委员会委员；国家药物筛选中心主任。
杜冠华教授于1995年获北京协和医学院博士学位，1995年至1998年在比利时列日大学从事博士后研究。他主要从事心脑血管和神经退行性疾病领域的药理学研究和新药发现与开发研究。他在中国建立了国家高通量药物筛选系统，并为国内制药机构或企业提供药物筛选服务。
近10年来，杜教授发表药理学研究论文600余篇，出版学术专著30余部，申请专利90余项，完成4种新药的临床前研究。他还担任Pharmacology & Therapeutics等十多本科学期刊的副主编。
《药理研究：现代中医（英文）》作者指南
（Pharmacological Reseach-Modern Chinese Medicine）
【官网信息】
Guide for Authors
We welcome articles on classic TCM reporting on clinical efficacy and safety of whole preparations or single pharmacologically active substances, done with modern approaches but linked to the traditional approach of Chinese medicine. Studies reporting also on the mechanisms of actions of the active substance(s) investigated are encouraged. Only acceptable are reports on standardised preparations. The diseases investigated have to be classified according to the WHO International Classification of Diseases version 11. The Journal will not consider articles utilising material from endangered specie as categorised by the International Union for Conservation of Nature.
Types of article
Original articles, Review articles, Correspondence. Case reports may be submitted as Correspondence.
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
Author checklist for Original Articles
The concern about the reproducibility of published results is growing in the scientific community. Pharmacological Research ?Modern Chinese medicine has thus implemented an author checklist in order to help the authors to increase the overall quality of the articles they publish with us and ensure better transparency and reproducibility of their results. The author checklist can be downloaded at https://www.elsevier.com/__data/promis_misc/Author checklist.docx To have a detailed explanation of the reasons and the rationale behind each item please go to http://www.ncbi.nlm.nih.gov/pubmed/26523875. A positive response to items 1-6 is mandatory for the further processing of the research manuscript. A negative response to the remaining items will not per se preclude the processing of the manuscript. The relevance of each item will depend on its relative relevance in the context of the manuscript, an aspect that will be evaluated by the Editor and the Reviewers, alongside the manuscript itself, to reach a fair decision. In the checklist there is also a free text area in which we ask for suggestions and advice from the authors. Pharmacological Research is not a top-down journal and we are building a community of scientists that helps enhancing the quality of the Journal; hence we will appreciate comments and feedbacks from the authors on how to improve the checklist in the next months. The checklist will not be requested for reviews.
Ethics in publishing
Please see our information on Ethics in publishing.
Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.
……
更多详情：
https://www.elsevier.com/journals/pharmacological-research-modern-chinese-medicine/2667-1425/guide-for-authors
